Literature DB >> 33947911

GPCR_LigandClassify.py; a rigorous machine learning classifier for GPCR targeting compounds.

Marawan Ahmed1, Horia Jalily Hasani1, Subha Kalyaanamoorthy1,2, Khaled Barakat3,4.   

Abstract

The current study describes the construction of various ligand-based machine learning models to be used for drug-repurposing against the family of G-Protein Coupled Receptors (GPCRs). In building these models, we collected > 500,000 data points, encompassing experimentally measured molecular association data of > 160,000 unique ligands against > 250 GPCRs. These data points were retrieved from the GPCR-Ligand Association (GLASS) database. We have used diverse molecular featurization methods to describe the input molecules. Multiple supervised ML algorithms were developed, tested and compared for their accuracy, F scores, as well as for their Matthews' correlation coefficient scores (MCC). Our data suggest that combined with molecular fingerprinting, ensemble decision trees and gradient boosted trees ML algorithms are on the accuracy border of the rather sophisticated deep neural nets (DNNs)-based algorithms. On a test dataset, these models displayed an excellent performance, reaching a ~ 90% classification accuracy. Additionally, we showcase a few examples where our models were able to identify interesting connections between known drugs from the Drug-Bank database and members of the GPCR family of receptors. Our findings are in excellent agreement with previously reported experimental observations in the literature. We hope the models presented in this paper synergize with the currently ongoing interest of applying machine learning modeling in the field of drug repurposing and computational drug discovery in general.

Entities:  

Year:  2021        PMID: 33947911     DOI: 10.1038/s41598-021-88939-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  82 in total

1.  Cardioprotection by resveratrol: a review of effects/targets in cultured cells and animal tissues.

Authors:  Joseph M Wu; Tze-Chen Hsieh; Zhirong Wang
Journal:  Am J Cardiovasc Dis       Date:  2011-04-27

2.  Overcoming the legal and regulatory barriers to drug repurposing.

Authors:  Alasdair Breckenridge; Robin Jacob
Journal:  Nat Rev Drug Discov       Date:  2018-06-08       Impact factor: 84.694

Review 3.  Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery.

Authors:  X Liu; F Zhu; X H Ma; Z Shi; S Y Yang; Y Q Wei; Y Z Chen
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 4.  Neuroprotective properties of resveratrol in different neurodegenerative disorders.

Authors:  Diego Albani; Letizia Polito; Alessandra Signorini; Gianluigi Forloni
Journal:  Biofactors       Date:  2010 Sep-Oct       Impact factor: 6.113

Review 5.  Antiviral activity of resveratrol.

Authors:  Michela Campagna; Carmen Rivas
Journal:  Biochem Soc Trans       Date:  2010-02       Impact factor: 5.407

6.  The development of the retinogeniculate pathways in normal and albino ferrets.

Authors:  J Cucchiaro; R W Guillery
Journal:  Proc R Soc Lond B Biol Sci       Date:  1984-12-22

Review 7.  Drug repurposing: progress, challenges and recommendations.

Authors:  Sudeep Pushpakom; Francesco Iorio; Patrick A Eyers; K Jane Escott; Shirley Hopper; Andrew Wells; Andrew Doig; Tim Guilliams; Joanna Latimer; Christine McNamee; Alan Norris; Philippe Sanseau; David Cavalla; Munir Pirmohamed
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

8.  Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs.

Authors:  Jennifer Kouznetsova; Wei Sun; Carles Martínez-Romero; Gregory Tawa; Paul Shinn; Catherine Z Chen; Aaron Schimmer; Philip Sanderson; John C McKew; Wei Zheng; Adolfo García-Sastre
Journal:  Emerg Microbes Infect       Date:  2014-12-17       Impact factor: 7.163

Review 9.  Polypharmacology or Promiscuity? Structural Interactions of Resveratrol With Its Bandwagon of Targets.

Authors:  Uzma Saqib; Tanya T Kelley; Siva K Panguluri; Dongfang Liu; Rajkumar Savai; Mirza S Baig; Stephan C Schürer
Journal:  Front Pharmacol       Date:  2018-10-24       Impact factor: 5.810

Review 10.  Changing R&D models in research-based pharmaceutical companies.

Authors:  Alexander Schuhmacher; Oliver Gassmann; Markus Hinder
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531

View more
  1 in total

1.  pdCSM-GPCR: predicting potent GPCR ligands with graph-based signatures.

Authors:  João Paulo L Velloso; David B Ascher; Douglas E V Pires
Journal:  Bioinform Adv       Date:  2021-11-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.